CA3192158A1 - 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds - Google Patents
2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compoundsInfo
- Publication number
- CA3192158A1 CA3192158A1 CA3192158A CA3192158A CA3192158A1 CA 3192158 A1 CA3192158 A1 CA 3192158A1 CA 3192158 A CA3192158 A CA 3192158A CA 3192158 A CA3192158 A CA 3192158A CA 3192158 A1 CA3192158 A1 CA 3192158A1
- Authority
- CA
- Canada
- Prior art keywords
- pyridin
- ino
- methanone
- fluorocyclopropyl
- idazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078372P | 2020-09-15 | 2020-09-15 | |
| US63/078,372 | 2020-09-15 | ||
| PCT/IB2021/058378 WO2022058890A1 (en) | 2020-09-15 | 2021-09-14 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3192158A1 true CA3192158A1 (en) | 2022-03-24 |
Family
ID=80739409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3192158A Pending CA3192158A1 (en) | 2020-09-15 | 2021-09-14 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11744824B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4214207A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023541464A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230067669A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116457355B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021342777A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192158A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022058890A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120603826A (zh) * | 2022-12-30 | 2025-09-05 | 广州市联瑞制药有限公司 | 双环类化合物及其制备方法和应用 |
| KR20260114565A (ko) * | 2023-11-15 | 2026-07-22 | 씨엠에스 리서치 앤드 디벨롭먼트 피티이. 리미티드 | 6,5-융합 헤테로아릴 유도체 및 이의 용도 |
| TW202525805A (zh) * | 2023-12-29 | 2025-07-01 | 大陸商廣州市聯瑞製藥有限公司 | 雙環類化合物及其製備方法和應用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4097483A (en) | 1974-11-01 | 1978-06-27 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolo 1,5-a!pyridines |
| JPS5154583A (en) * | 1974-11-01 | 1976-05-13 | Kyorin Seiyaku Kk | Shinkipirazoro * 1 55a * pirijinjudotaino seizoho |
| JP2007529496A (ja) * | 2004-03-19 | 2007-10-25 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体 |
| KR20080002866A (ko) | 2005-04-25 | 2008-01-04 | 노파르티스 아게 | 펩티드 데포르밀라제 (pdf) 억제제로서 유용한이미다조(1,2-a)피리딘 유도체 |
| PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| JP5352452B2 (ja) * | 2006-06-06 | 2013-11-27 | メディシノバ, インコーポレイテッド | 置換ピラゾロ[1,5−a]ピリジン化合物およびその使用方法 |
| CA2825746A1 (en) | 2011-01-26 | 2012-08-02 | Kyorin Pharmaceutical Co. Ltd. | Pyrazolopyridine derivative or pharmacologically acceptable salt thereof |
| US20150158868A1 (en) | 2013-12-06 | 2015-06-11 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CN108084193A (zh) * | 2017-12-19 | 2018-05-29 | 郭守东 | 一种brd4蛋白抑制剂 |
| KR102906523B1 (ko) * | 2018-09-13 | 2025-12-30 | 브리스톨-마이어스 스큅 컴퍼니 | 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드 |
-
2021
- 2021-09-14 US US17/474,293 patent/US11744824B2/en active Active
- 2021-09-14 AU AU2021342777A patent/AU2021342777A1/en active Pending
- 2021-09-14 JP JP2023517408A patent/JP2023541464A/ja active Pending
- 2021-09-14 CN CN202180063093.0A patent/CN116457355B/zh active Active
- 2021-09-14 KR KR1020237012894A patent/KR20230067669A/ko active Pending
- 2021-09-14 CA CA3192158A patent/CA3192158A1/en active Pending
- 2021-09-14 WO PCT/IB2021/058378 patent/WO2022058890A1/en not_active Ceased
- 2021-09-14 EP EP21868834.9A patent/EP4214207A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4214207A4 (en) | 2024-10-02 |
| CN116457355A (zh) | 2023-07-18 |
| JP2023541464A (ja) | 2023-10-02 |
| US11744824B2 (en) | 2023-09-05 |
| US20220087985A1 (en) | 2022-03-24 |
| EP4214207A1 (en) | 2023-07-26 |
| WO2022058890A1 (en) | 2022-03-24 |
| AU2021342777A1 (en) | 2023-04-27 |
| KR20230067669A (ko) | 2023-05-16 |
| AU2021342777A9 (en) | 2024-05-30 |
| CN116457355B (zh) | 2026-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113454082B (zh) | 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途 | |
| CN106715430B (zh) | 抑制瞬时型感受器电位a1离子通道 | |
| CN102341400A (zh) | 用作激酶抑制剂的吡咯并嘧啶化合物 | |
| KR20120007540A (ko) | PI3 키나제 및/또는 mTOR의 억제제 | |
| US11744824B2 (en) | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | |
| WO2018140648A1 (en) | Pyrrolopyrimidine itk inhibitors for treating inflammation and cancer | |
| BR112021009309A2 (pt) | compostos heteroaromáticos adicionais com atividade contra rsv | |
| JP2024502106A (ja) | c-MYC mRNA翻訳調節因子及び癌治療におけるそれの使用 | |
| EP4200299B1 (en) | Compounds for prevention or treatment of neurodegenerative disorders | |
| HK40096261A (en) | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | |
| US20210221820A1 (en) | Compounds for the modulation of myc activity | |
| HK40058868A (en) | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250905 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250905 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250909 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250909 |